Standout Papers

Recommendations for Chamber Quantification: A Report from the American Society of Echocardiogra... 2005 2026 2012 2019 9.2k
  1. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology (2005)
    Roberto M. Lang, Michelle Bierig et al. Journal of the American Society of Echocardiography
  2. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography (2010)
    Lawrence Rudski, Wyman W. Lai et al. Journal of the American Society of Echocardiography
  3. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure (2014)
    John J.V. McMurray, Milton Packer et al. New England Journal of Medicine
  4. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events (2009)
    Arthur J. Moss, William J. Hall et al. New England Journal of Medicine
  5. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (2015)
    Marc A. Pfeffer, Brian Claggett et al. New England Journal of Medicine
  6. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both (2003)
    Marc A. Pfeffer, John J.V. McMurray et al. New England Journal of Medicine
  7. Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention (2005)
    Scott D. Solomon, John J.V. McMurray et al. New England Journal of Medicine
  8. Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction (2004)
    Nagesh S. Anavekar, John J.V. McMurray et al. New England Journal of Medicine
  9. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease (2009)
    Marc A. Pfeffer, Emmanuel A. Burdmann et al. New England Journal of Medicine
  10. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 (2020)
    Muthiah Vaduganathan, Orly Vardeny et al. New England Journal of Medicine
  11. Potential Effects of Coronaviruses on the Cardiovascular System (2020)
    Mohammad Madjid, Payam Safavi‐Naeini et al. JAMA Cardiology
  12. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial (2012)
    Scott D. Solomon, Michael R. Zile et al. The Lancet
  13. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes (2012)
    Hans‐Henrik Parving, Barry M. Brenner et al. New England Journal of Medicine
  14. Celecoxib for the Prevention of Colorectal Adenomatous Polyps (2006)
    Nadir Arber, Craig Eagle et al. New England Journal of Medicine
  15. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial (2008)
    Philippe Menasché, Ottavio Alfieri et al. Circulation
  16. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients (2005)
    Scott D. Solomon, Nagesh S. Anavekar et al. Circulation
  17. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT) (2011)
    Wojciech Zaręba, Helmut Klein et al. Circulation
  18. Mutations in Sarcomere Protein Genes as a Cause of Dilated Cardiomyopathy (2000)
    Mitsuhiro Kamisago, Sapna Sharma et al. New England Journal of Medicine
  19. Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both (2005)
    Scott D. Solomon, John J.V. McMurray et al. New England Journal of Medicine
  20. Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction (2013)
    Elisabeth Kraigher‐Krainer, Amil M. Shah et al. Journal of the American College of Cardiology
  21. Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction (2002)
    Ellen O. Weinberg, Masahisa Shimpo et al. Circulation
  22. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme (2008)
    Michael R. MacDonald, Mark C. Petrie et al. European Heart Journal
  23. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis (2018)
    Sara B. Seidelmann, Brian Claggett et al. The Lancet Public Health
  24. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials (2022)
    Muthiah Vaduganathan, Kieran F. Docherty et al. The Lancet
  25. Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis (2014)
    Hajime Uno, Brian Claggett et al. Journal of Clinical Oncology
  26. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction (2019)
    James L. Januzzi, Margaret F. Prescott et al. JAMA
  27. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure (2013)
    Karl Swedberg, James B. Young et al. New England Journal of Medicine
  28. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction (2017)
    Viviany R. Taqueti, Scott D. Solomon et al. European Heart Journal
  29. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus (2018)
    Karin Rådholm, Gemma A. Figtree et al. Circulation
  30. Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF) (2013)
    John J.V. McMurray, Milton Packer et al. European Journal of Heart Failure
  31. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction (2015)
    Scott D. Solomon, Brian Claggett et al. European Heart Journal
  32. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone (2015)
    Amil M. Shah, Brian Claggett et al. Circulation
  33. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis (2019)
    Scott D. Solomon, David Adams et al. Circulation
  34. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients (2015)
    Akshay S. Desai, John J.V. McMurray et al. European Heart Journal
  35. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure (2018)
    Kevin Damman, Mauro Gori et al. JACC Heart Failure
  36. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction (2015)
    Mihai Gheorghiade, Stephen J. Greene et al. JAMA
  37. Heart Failure with Mid-Range Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan Across the Entire Ejection Fraction Spectrum (2018)
    Lars H. Lund, Brian Claggett et al. European Journal of Heart Failure
  38. A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF) (2019)
    John J.V. McMurray, David L. DeMets et al. European Journal of Heart Failure
  39. Heart failure with preserved ejection fraction: from mechanisms to therapies (2018)
    Carolyn S.P. Lam, Adriaan A. Voors et al. European Heart Journal
  40. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction (2019)
    Akshay S. Desai, Scott D. Solomon et al. JAMA
  41. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction (2020)
    Paul W. Armstrong, Carolyn S.P. Lam et al. JAMA
  42. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial (2021)
    Scott D. Solomon, Rudolf A. de Boer et al. European Journal of Heart Failure
  43. Clinical Characteristics and Outcomes of Hospitalized Women Giving Birth With and Without COVID-19 (2021)
    Karola Jering, Brian Claggett et al. JAMA Internal Medicine
  44. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction (2021)
    David D. Berg, Pardeep S. Jhund et al. JAMA Cardiology
  45. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF (2021)
    James P. Curtain, Kieran F. Docherty et al. European Heart Journal
  46. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox (2023)
    Jawad H. Butt, Mark C. Petrie et al. European Heart Journal
  47. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria (2023)
    Brendon L. Neuen, Hiddo J.L. Heerspink et al. Circulation
  48. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure (2023)
    Robert J. Mentz, Jonathan H. Ward et al. Journal of the American College of Cardiology
  49. Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial (2025)
    Alexander Peikert, Muthiah Vaduganathan et al. European Heart Journal

Immediate Impact

1 by Nobel laureates 3 from Science/Nature 77 standout
Sub-graph 1 of 18

Citing Papers

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
2023 Standout
Blinded, randomized trial of sonographer versus AI cardiac function assessment
2023 StandoutNature
11 intermediate papers

Works of Scott D. Solomon being referenced

Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography
2010 Standout
Echocardiographic Imaging in Clinical Trials: American Society of Echocardiography Standards for Echocardiography Core Laboratories
2009
and 16 more

Author Peers

Author Last Decade Papers Cites
Scott D. Solomon 62893 12767 13597 13122 1.1k 89.8k
Marc A. Pfeffer 62884 17255 8773 25888 593 94.5k
Martin G. Larson 51911 9351 7780 12342 580 86.7k
John J.V. McMurray 84097 29299 16068 22055 1.5k 126.4k
Emelia J. Benjamin 68687 8206 9271 11568 766 98.8k
Gregg C. Fonarow 76391 9723 13621 17156 1.8k 109.2k
Ramachandran S. Vasan 55741 15602 8590 13453 941 105.1k
Daniel Levy 88384 18947 10913 24628 807 138.9k
Aaron R. Folsom 26297 10042 8230 10864 859 73.5k
William B. Kannel 69673 25140 10138 22477 475 125.2k
Deepak L. Bhatt 55509 22590 13898 38853 2.0k 103.4k

All Works

Loading papers...

Rankless by CCL
2026